Navigation Links
Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology
Date:7/24/2014

CAMPBELL, Calif., July 24, 2014 /PRNewswire/ -- Lazarus Effect, a medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, announced today that the United States Patent and Trademark Office has issued a new patent (U.S. Patent Number 8,795,305) covering core technology behind the company's Lazarus CoverTM and ReCoverTM devices.

The Lazarus ReCover is a single-component stent-retriever (stentriever) with an integrated, novel, cover-based protection mechanism integrated onto the device. It is designed to cover and protect thrombus and to prevent loss of emboli during thrombectomy (clot removal) procedures. The Lazarus Cover is a unique, nitinol mesh cover that can be used with a variety of available retriever devices (including stentrievers) to protect the captured contents against loss during removal from the blood vessel.   

"This latest patent provides strong protection for Lazarus Effect technology that covers and protects captured content during retrieval procedures," said Martin Dieck, chairman and CEO, Lazarus Effect. "This patent will be a cornerstone in a series of Lazarus Effect patents relating to protected - and therefore improved - retrieval procedures."

The issued patent adds to the comprehensive patent portfolio Lazarus Effect has been building. The company currently has five issued US patents and numerous pending US and worldwide patent applications, including a patent issued in May 2014 covering additional technology related to the removal of clots in the brain. The Lazarus ReCover device has CE Mark for use in Europe. The Lazarus Cover device is pending CE Mark. Neither device is approved for sale in the United States.

About Lazarus Effect

Lazarus Effect is developing a complete portfolio of vascular-device products, including several to treat ischemic stroke, based on a patented, wire-frame technology platform.

Forward-looking Statements

Statements contained in this press release about Lazarus Effect, Inc. that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include changes in market or financial conditions, and other changes beyond the control of the Company. The Company specifically disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Lazarus Effect
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idecs Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
2. New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
3. Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
4. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
5. ObamaCare: Health Care Reform and its Effect on Sleep Apnea
6. Improving the Quality and Effectiveness of Marketing Services Groups in an Environment Characterized by Globalization and Shrinking Resources
7. New England Journal of Medicine releases study showing GSKs FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
8. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
9. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
10. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
11. Ensuring Critical Leadership Messages are Effectively Communicated Across an Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):